Rivastigmine transdermal compositions and methods of using the same

1. A transdermal composition, the composition comprising:

an active agent layer comprising:

rivastigmine present in an amount of 10% w/w or more;

an adhesive component comprising one or more pressure sensitive adhesives; and

a solubility modulator component that is distinct from the adhesive component comprising a crosslinked acrylic acid polymer in an amount of from 3% to 7% w/w; and

a backing.

2. The composition according to claim 1 , wherein the rivastigmine is present in an amount of from 10% to 75% w/w.

3. The composition according to claim 1 , wherein the solubility modulator is a solubility enhancer.

4. The composition according to claim 1 , wherein the active agent layer comprises a copolymer of butyl methacrylate and methyl methacrylate.

5. The composition according to claim 1 , wherein the active agent layer comprises an antioxidant.

6. The composition according to claim 1 , wherein the active agent layer is configured as a single layer topical formulation.

7. The composition according to claim 1 , wherein the transdermal composition comprises an adhesive layer disposed on a side of the active agent layer opposite the backing.

8. The composition according to claim 7 , wherein the adhesive layer comprises a pressure-sensitive adhesive.

9. The composition according to claim 7 , wherein the composition comprises a membrane disposed between the active agent layer and the adhesive layer.

10. The composition according to claim 1 , wherein the composition comprises a second active agent layer disposed between the backing and the active agent layer.

11. The composition according to claim 1 , wherein the composition provides a flux of from 1 to 20 μg/cm 2 /hr for a period of 5 or more days when applied to a skin site of a subject.

12. The composition according to claim 1 , wherein the composition provides a Cmin/Cmax of 0.4 or more for a period of 5 or more days when applied to a skin site of a subject.

13. A method comprising:

applying to a skin site of a subject a transdermal composition according to claim 1 in a manner sufficient to achieve a therapeutic flux of the rivastigmine for an extended period of time.

14. The method according to claim 13 , wherein the subject is suffering from dementia.

15. The method according to claim 14 , wherein the dementia is associated with Alzheimer's disease or Parkinson's disease.

16. A kit comprising two or more transdermal compositions according to claim 1 .

17. The composition according to claim 1 , wherein the solubility modulator comprises an acrylic acid homopolymer.

18. The composition according to claim 1 , wherein the composition further comprises an adhesive layer, the adhesive layer comprising a pressure sensitive adhesive that is different from the pressure sensitive adhesive of the active agent layer.

19. The composition according to claim 18 , wherein the pressure sensitive adhesive in the active agent layer comprises an acrylate copolymer having pendant —COOH functional groups and the pressure sensitive adhesive in the adhesive layer comprises an acrylate copolymer that lacks pendant functional groups.

20. The composition according to claim 1 , wherein the active agent layer comprises:

rivastigmine present in an amount of 10% w/w or more;

an adhesive component comprising one or more pressure sensitive adhesives;

a solubility modulator component that is distinct from the adhesive component comprising a crosslinked acrylic acid polymer in an amount of from 3% to 7% w/w;

a copolymer of butyl methacrylate and methyl methacrylate; and

an antioxidant.

21. The composition according to claim 1 , wherein the active agent layer consists of:

rivastigmine;

a pressure sensitive adhesive;

a solubility modulator comprising a crosslinked acrylic acid polymer that is distinct from the pressure sensitive adhesive;

a copolymer of butyl methacrylate and methyl methacrylate; and

an antioxidant.